Pralmorelin · GHRP2
GHRP-2 (Growth Hormone Releasing Peptide-2, Pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist that stimulates GH release from the anterior pituitary. It is more potent than Ipamorelin but less selective, significantly increasing appetite (via ghrelin pathway), mildly elevating cortisol and prolactin at higher doses. GHRP-2 was one of the first GHRPs developed and has been approved in Japan (Pralmorelin) for GH deficiency diagnosis. It produces robust GH pulses but the appetite stimulation and cortisol/prolactin effects make Ipamorelin preferred in most modern protocols.
Fasted 2+ hours. Bedtime preferred. Can split into 2-3 daily doses, each fasted. Stronger hunger signal than Ipamorelin.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
GHRP-2 binds GHS-R1a (ghrelin receptor) with higher affinity than Ipamorelin, producing stronger GH release. Unlike Ipamorelin, it also activates hypothalamic appetite centers (ghrelin-mediated hunger) and mildly stimulates ACTH/cortisol and prolactin release at standard doses. Best paired with a GHRH analog for synergistic dual-pathway stimulation.
Days 1-7: Strong hunger. Sleep improvements.
Weeks 2-6: Body composition changes beginning.
Weeks 6-16: Full effects with GHRH analog.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Healthy men received 100 mcg GHRP-2 by daily SubQ injection for five days.
To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days.
Evidence scope. Human, nine healthy men; once daily only.
GHRP-2 is a ghrelin agonist binding the GH-secretagogue receptor.
GHRP-2 is a synthetic agonist of ghrelin, the newly-discovered gut peptide which binds to the growth hormone (GH) secretagogue receptor.
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.
Evidence scope. Exact molecule; mechanism only.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Full 100-200 mcg 1-3x/day fasted/bedtime schedule. Only 100 mcg once daily was verified.
Water retention and SubQ cortisol/prolactin elevation. The endocrine abstract used IV route and was rejected.
Stronger than Ipamorelin
Confirmed. Higher GH release per dose but at cost of appetite stimulation and cortisol/prolactin elevation.
Confirmed via ghrelin pathway. Therapeutic advantage in wasting conditions, disadvantage in weight management.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
SubQ
GH pulse lasts 2-3 hours; downstream IGF-1 elevation persists longer
Enzymatic degradation and renal clearance
Storage. Standard BAC water 2-8C. 28 days.
Approved in Japan as Pralmorelin. Not FDA-approved. WADA prohibited under S2.
Put it to work
Open GHRP-2 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open GHRP-2 in the app →Go deeper
The complete GHRP-2 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.